Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

MCRB Seres Therapeutics Inc

1,11

0,04 (3,74%)

06 Juin 2024 - Fermé

Retardé de 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Seres Therapeutics (NASDAQ:MCRB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Plus de graphiques de la Bourse Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024

Plus de graphiques de la Bourse Seres Therapeutics

Actualités Seres Therapeutics Inc

Form 4 - Statement of changes in beneficial ownership of securities
Samedi 18 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samedi 18 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samedi 18 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samedi 18 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samedi 18 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercredi 8 Mai 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Mercredi 8 Mai 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Mercredi 8 Mai 2024 ( il y a 4 semaines) • Business Wire

Form 8-K - Current report
Mardi 7 Mai 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lundi 6 Mai 2024 ( il y a 1 mois) • Business Wire

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
Lundi 6 Mai 2024 ( il y a 1 mois) • Business Wire

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Mardi 9 Avril 2024 ( il y a 2 mois) • Business Wire

Plus d'articles sur Seres Therapeutics Inc

NLBNPIT1X9T5 20240918 5000

Fedral Gold Coin

NLBNPIT1XYN6 20240621 21...

Fidelity Disruptive Medi...

NLBNPIT1X9J6 20991231 87...

Viveve Medical (CE)

Gravitas III Capital

Mid America Apartment Co...

Hsbc Msci Em Sc

Vivesto AB (CE)

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales